Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-dose, Randomized, Open-label, Repeated Cross-over Pharmacokinetic Comparison Study of Two Formulations of Jaktinib Hydrochloride Tablets in Healthy Adult Volunteers Under Fasted Conditions

NCT06132243 is registered in ClinicalTrials.gov with Suzhou Zelgen Biopharmaceuticals Co.,Ltd as lead sponsor.

NCT NCT06132243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06132243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-dose, Randomized, Open-label, Repeated Cross-over Pharmacokinetic Comparison Study of Two Formulations of Jaktinib Hydrochloride Tablets in Healthy Adult Volunteers Under Fasted Conditions
Lead sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase
Phase 1
Overall status
Completed
Start date
November 29, 2023
Completion date
December 20, 2023
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis